| Quantity | 1 mg, 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg | 5 mg, 10 mg | 25 mg, 50 mg, 100 mg | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | C16G2 TFA is a specific targeted antimicrobial peptide (STAMP) that targets the cariogenic oral pathogen Streptococcus mutans. C16G2 TFA specifically recognizes and disrupts the bacterial cell membrane, causing small molecule leakage and loss of membrane potential, leading to bacterial killing. C16G2 TFA is a specific targeted antimicrobial peptide (STAMP) that targets the cariogenic oral pathogen Streptococcus mutans. C16G2 TFA specifically recognizes and disrupts the bacterial cell membrane, causing small molecule leakage and loss of membrane potential, leading to bacterial killing. C16G2 TFA exhibits higher selectivity and efficacy against Streptococcus mutans, unlike broad-spectrum antimicrobial peptides[1]... Read More | ACTH (7-38) (human) is the 7-38 fragment of human ACTH (1-39). human ACTH (1-39), known as a corticotropin inhibitory peptide (CIP), is an antagonist of the ACTH receptor and has no any corticosteroid activity[1] | Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure[1]. Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure[1]. Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release[2]... Read More | Gramicidin is an antimicrobial peptide assembling as channels in membranes and increasing their permeability towards cations | Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis[1][2][3][4][5][6]... Read More |